A study involving nearly 600 women from clinics in California, Colorado, Illinois, Kansas, and Minnesota challenges the necessity of the FDA's Patient Agreement Form for mifepristone, arguing women already know the risks of chemical abortion pills. However, the study reveals significant gaps in patient knowledge about correct usage and failure rates, underscoring the importance of these forms to ensure women are fully informed and protected.
Read →Loading search…